The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.

Abstract

These data indicate that inhibiting endogenous PPARγ signaling may be a promising new approach to breast cancer therapy.